13 results on '"L. Iñiguez"'
Search Results
2. Regional Anesthesia in Times of COVID-19
- Author
-
M. Whizar-Lugo, Víctor, primary, L. Iñiguez-López, Karen, additional, and Castorena-Arellano, Guillermo, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Spinal Anesthesia in Pediatrics
- Author
-
Hernández-Cortez, Enrique, primary, M. Martínez-Barragán, Yolanda, additional, and L. Iñiguez-Lopéz, Karen, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Regional Anesthesia for Shoulder and Clavicle Surgery
- Author
-
Alfonso Rodríguez-Gómez, Ciro, primary, Ramón Saucillo-Osuna, José, additional, and L. Iñiguez-López, Karen, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Regional Anesthesia in Times of COVID-19
- Author
-
Víctor M. Whizar-Lugo, Karen L. Iñiguez-López, and Guillermo Castorena-Arellano
- Abstract
The globalized coronavirus pandemic 2019 has kept us on our toes. Although confusion is widespread and there is a trend toward normalization of almost all human activities, outbreaks remain frequent. The majority of patients with COVID-19 have a trivial to moderate clinical course; a small group develops severe pneumonia and other life-threatening complications. Vaccination against this virus has contributed to better control of the pandemic, but there are no antiviral drugs that have demonstrated efficacy; therefore, the management of surgical patients confirmed or suspected of this disease is a challenge for health care workers, including the anesthesiologists, as well as the non-COVID-19 patients who at a given moment could become carriers or sick. General anesthesia produces aerosols and risks medical and technical personnel being infected, especially those who manage the airway. On the other hand, regional anesthesia has advantages over general anesthesia because the airway is not handled; however, its limited duration is the most important concern. It is reasonable that regional anesthesia occupies a preponderant place in the safe management of all patients, as long as the type of surgery allows it, the anesthesiologist has sufficient skills and patients accept the proposed technique. At this time of globalized crisis due to COVID-19, the intrapandemic anesthetic management of patients undergoing surgery continues to be a changing task, a challenge that has been solved as new data based on solid scientific evidence arise, besides the development of drugs, safer vaccines, equipment, and health prophylactic methods. There is a clear tendency to use regional anesthesia whenever this is possible.
- Published
- 2022
6. Regional Anesthesia for Shoulder and Clavicle Surgery
- Author
-
Ciro Alfonso Rodríguez-Gómez, José Ramón Saucillo-Osuna, and Karen L. Iñiguez-López
- Abstract
The shoulder joint and clavicle are innervated by the brachial plexus, the cervical plexus, and nerves to muscles around the joint and clavicle. Regional anesthesia is aimed at producing optimal surgical conditions, prolonging postoperative analgesia, being free of complications, reducing costs, and minimizing hospital stay. Regional upper extremity anesthesia can be achieved by blocking the brachial plexus at different stages along the course of the trunks, divisions, cords, and terminal branches. The gold standard of regional anesthesia for shoulder surgery is interscalene brachial plexus block plus cervical plexus block, but it is associated with a high rate of neurological complications and phrenic nerve block. The interest of the anesthesiologist has been directed towards regional blocks avoiding these complications; techniques that approach nerves more distally than interscalene block have been described. These approaches include supraclavicular nerves, upper trunk, suprascapular nerve by anterior approach, axillary nerve block in the axillary fossa, clavipectoral fascia block. The objective of this chapter is to describe the anatomy, sonoanatomy, technique, and the clinical utility of these accesses.
- Published
- 2022
7. Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
- Author
-
Eugenio De Miguel, Jesús T Sanchez-Costa, Paula Estrada, Alejandro Muñoz, Cristina Valero Martínez, Patricia Moya Alvarado, María Jesús García-Villanueva, Vanessa A Navarro Angeles, Carlos Galisteo Lencastre Da Veiga, Anne Riveros Frutos, Jose A Román Ivorra, Selena Labrada Arrabal, Margarida Vasques Rocha, Carlota L Iñiguez, María García-Gonzalez, Clara Molina-Almeda, María Alcalde Villar, Antonio Juan Mas, Miguel A Gonzalez-Gay, Ricardo Blanco, and Universidad de Cantabria
- Subjects
Rheumatology ,Positron-Emission Tomography ,Giant Cell Arteritis ,Immunology ,Systemic vasculitis ,Humans ,Immunology and Allergy ,Female ,Temporal Arteries ,Retrospective Studies ,Ultrasonography - Abstract
Objective The main study objective was to determine how giant cell arteritis (GCA) is diagnosed in our clinical practice and whether the EULAR recommendations have influenced the diagnostic procedures used. Methods ARTEritis of the Rheumatology Spanish Society -Sociedad Española de Reumatología (ARTESER) is a multicentre observational retrospective study conducted in 26 hospitals with support from the Spanish Society of Rheumatology. All patients diagnosed with GCA between 1 June 2013 and 29 March 2019 were included. The gold standard for the diagnosis of GCA was the judgement of the physician in charge, according to clinical criteria, supported by data available from laboratory tests, imaging studies (ultrasound, positron emission tomography (PET) and MRI/CT angiography) and temporal artery biopsy (TAB) when available. Results We included 1675 patients with GCA (mean age±SD (76.9±8.1) years, 1178women (70.3%)). Of these, 776 patients had a positive TAB (46.3%), 503 (30.0%) positive ultrasound, 245 positive PET (14.6%) and 64 positive MRI/CT angiography (3.8%). These percentages changed substantially over the study. From 2013 to 2019, the use of ultrasound in diagnosis grew from 25.8% to 52.9% and PET from 12.3% to 19.6%, while use of TAB decreased from 50.3% to 33.3%. Conclusions Biopsy was the most widely used diagnostic test for confirming GCA, but use of imaging as a diagnostic tool has grown in recent years. Following publication of the 2018 EULAR recommendations, ultrasound has displaced biopsy as the first-line diagnostic test; TAB was performed in a third and PET in a fifth of cases. Funding: Roche contributes to the financial support of this study. Acknowledgements: To the Spanish Society of Rheumatology that has promoted and provided coverage for this study. To Roche for its financial contribution that made this epidemiological study possible
- Published
- 2022
- Full Text
- View/download PDF
8. Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry
- Author
-
Juan Molina-Collada, Marta Domínguez-Álvaro, Rafael B. Melero-González, Eugenio de Miguel, Maite Silva-Díaz, Jesús Alejandro Valero Jaimes, Ismael González, Julio Sánchez Martín, Javier Narváez, Joan Calvet, Ivette Casafont-Solé, Jose A Román Ivorra, Selene Labrada Arrabal, Margarida Vasques Rocha, Carlota L Iñiguez, María Sagrario Bustabad Reyes, Cristina Campos Fernández, María Alcalde Villar, Antonio Juan Mas, Ricardo Blanco, and on behalf of the ARTESER Project Collaborative Group
- Subjects
Mortality ,Survival ,Giant cell arteritis ,Vasculitis ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Objectives To compare mortality rates between GCA patients and the general population in Spain, and to identify associated factors influencing mortality. Methods ARTESER, a multicenter registry by the Spanish Society of Rheumatology, includes GCA patients from June 2013 to March 2019. Demographic, clinical, imaging, histological and mortality data were collected retrospectively. Only patients with at least one year of follow-up were included for analysis. The mortality rates were expressed as the number of deaths per 1000 person-years, with 95% confidence interval (CI) by sex and age group. Kaplan-Meier method was performed for survival analysis. The factors influencing mortality were analyzed using Cox regression model. Results A total of 1200 patients with GCA were analyzed, with a mean (SD) follow-up of 2.18 (1.53) years. The overall five-year cumulative mortality rate (95%CI) was 37.86 (31.75-43.96) per 1000 patients/year. The cumulative mortality rate was significantly higher in males than females (59.04vs29.06; p
- Published
- 2025
- Full Text
- View/download PDF
9. Users' expectations of the new pre-exposure prophylaxis for the HIV modalities.
- Author
-
Jesus ML, Vargas MG, Iñiguez-Rueda L, Fernandez-Gonzalez E, Silva LAVD, Cabrera JM, Pérez F, and Saz J
- Subjects
- Humans, Male, Female, Adult, Interviews as Topic, Transgender Persons psychology, Administration, Oral, Middle Aged, Young Adult, Injections, Intramuscular, Pre-Exposure Prophylaxis methods, HIV Infections prevention & control, Anti-HIV Agents administration & dosage, Sexual and Gender Minorities psychology
- Abstract
This article aims to discuss the expectations of Homosexual Men, Bisexual Men and a Transgender Woman, who use or want to use an oral pre-exposure prophylaxis (PrEP) for the human immunodeficiency virus (HIV) about PrEP modalities. Sixteen PrEP users, who are followed up in the BCN Checkpoint, were interviewed,. The interviews were audio-recorded, subjected to thematic categorical analysis within the theoretical framework from the praxiographic perspective. They are all adapted to the use of daily oral and event-based PrEP. In relation to the new PrEP modalities (monthly pill; intramuscular injection every two months; subcutaneous injection every six months), they are all very receptive to these possibilities, but they lack information on the specificities of each and specific assessment of their needs. Comments about the use of oral PrEP are positive, and expectations regarding the new PrEP modalities are visibly high. However, the most important thing for the interviewees is the guarantee that they will have follow-up appointments to continue taking care of their affective-sexual health, which is not dependent on the type of PrEP modalities.
- Published
- 2024
- Full Text
- View/download PDF
10. [Angiographic result with the use of adenosine before percutaneous coronary intervention in pharmacoinvasive therapy].
- Author
-
Iñiguez-Loza L, Nucamendi-Solórzano FI, Solórzano-Vázquez MA, Urzúa-González AR, Hernández-González MA, and V OS
- Subjects
- Humans, Male, Female, Single-Blind Method, Prospective Studies, Middle Aged, Aged, Longitudinal Studies, Myocardial Infarction, Vasodilator Agents therapeutic use, Vasodilator Agents administration & dosage, Drug-Eluting Stents, Treatment Outcome, Mexico, Percutaneous Coronary Intervention methods, Adenosine therapeutic use, Adenosine administration & dosage, Coronary Angiography
- Abstract
Background: Mexico is the country with the highest mortality from acute myocardial infarction (AMI), which is why guidelines have been established for early reperfusion in which fibrinolysis is the second most accessible method. However, there is a percentage of patients who do not achieve acceptable myocardial perfusion and this is associated with adverse cardiovascular outcomes. Different adenosine schemes have been used as an adjuvant to restore adequate myocardial perfusion., Objective: To compare the final angiographic flow in patients undergoing pharmacoinvasive percutaneous coronary intervention (PCI) with the use of intracoronary adenosine versus patients without its use., Material and Methods: Single-center, prospective, longitudinal, single-blind study carried out in patients with AMI, thrombolyzed, with reperfusion data, sent to a tertiary care center from March 2022 to June 2023, randomized to receive intracoronary adenosine previous to intervention. Drug-eluting stents were placed in all patients. Initial and final angiographic flow was compared., Results: 33 patients were included, randomized 1:1 to control and intervention groups. 75.8% of the participants were male. The most frequent artery responsible for the infarction was the anterior descending (63.6%). An average of 350 mcg of intracoronary adenosine was used in the intervention group, and the most frequent complication in both groups was the presence of no-reflow phenomenon., Conclusions: Due to the small sample size, it is not possible to conclude the usefulness of adenosine for improving final angiographic flow in pharmacoinvasive PCI. More adverse effects were reported in the intervention group, without a significant statistical difference., (Licencia CC 4.0 (BY-NC-ND) © 2024 Revista Médica del Instituto Mexicano del Seguro Social.)
- Published
- 2024
- Full Text
- View/download PDF
11. Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.
- Author
-
Toledo-Romaní ME, Valenzuela-Silva C, Montero-Díaz M, Iñiguez-Rojas L, Rodríguez-González M, Martínez-Cabrera M, Puga-Gómez R, German-Almeida A, Fernández-Castillo S, Climent-Ruiz Y, Santana-Mederos D, López-González L, Morales-Suárez I, Doroud D, Valdés-Balbín Y, García-Rivera D, Van der Stuyft P, and Vérez-Bencomo V
- Abstract
Background: Increased pediatric COVID-19 occurrence due to the SARS-CoV-2 Omicron variant has raised concerns about the effectiveness of existing vaccines. The protection provided by the SOBERANA-02-Plus vaccination scheme against this variant has not yet been studied. We aimed to evaluate the scheme's effectiveness against symptomatic Omicron infection and severe disease in children., Methods: In September 2021, Cuba implemented a mass pediatric immunization with the heterologous SOBERANA-02-Plus scheme: 2 doses of conjugated SOBERANA-02 followed by a heterologous SOBERANA-Plus dose. By December, before the Omicron outbreak, 95.4% of 2-18 years-old had been fully immunized. During the entire Omicron wave, we conducted a nationwide longitudinal post-vaccination case-population study to evaluate the real-world effectiveness of the SOBERANA-02-Plus scheme against symptomatic infection and severe disease in children without previous SARS-CoV-2 infection. The identification of COVID-19 cases relied on surveillance through first line services, which refer clinical suspects to pediatric hospitals where they are diagnosed based on a positive RT-PCR test. We defined the Incidence Rate ratio (IRR) as IRvaccinated age group/IRunvaccinated 1-year-old and calculated vaccine effectiveness as VE = (1-IRR)∗100%. 24 months of age being the 'eligible for vaccination' cut-off, we used a regression discontinuity approach to estimate effectiveness by contrasting incidence in all unvaccinated 1-year-old versus vaccinated 2-years-old. Estimates in the vaccinated 3-11 years-old are reported from a descriptive perspective., Findings: We included 1,098,817 fully vaccinated 2-11 years-old and 98,342 not vaccinated 1-year-old children. During the 24-week Omicron wave, there were 7003/26,241,176 person-weeks symptomatic COVID-19 infections in the vaccinated group (38.2 per 10
5 person-weeks in 2-years-old and 25.5 per 105 person-weeks in 3-11 years-old) against 3577/2,312,273 (154.7 per 105 person-weeks) in the unvaccinated group. The observed overall vaccine effectiveness against symptomatic infection was 75.3% (95% CI, 73.5-77.0%) in 2-years-old children, and 83.5% (95% CI, 82.8-84.2%) in 3-11 years-old. It was somewhat lower during Omicron BA.1 then during Omicron BA.2 variant circulation, which took place 1-3 and 4-6 months after the end of the vaccination campaign. The effectiveness against severe symptomatic disease was 100.0% (95% CI not estimated) and 94.6% (95% CI, 82.0-98.6%) in the respective age groups. No child death from COVID-19 was observed., Interpretation: Immunization of 2-11 years-old with the SOBERANA-02-Plus scheme provided strong protection against symptomatic and severe disease caused by the Omicron variant, which was sustained during the six months post-vaccination follow-up. Our results contrast with the observations in previous real-world vaccine effectiveness studies in children, which might be explained by the type of immunity a conjugated protein-based vaccine induces and the vaccination strategy used., Funding: National Fund for Science and Technology (FONCI-CITMA-Cuba)., Competing Interests: MCRG, MMC, SFC, YCR, DSM, YVB, DGR and VVB are employees of the Finlay Vaccine Institute that developed and manufactures the SOBERANA vaccines. VVB, YVB, DGR, YCR, SFC and DSM are authors of two patent applications related with the vaccines. The other authors have no potential conflict of interest., (© 2024 The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
12. The impact of inclusion practices on the identity of people diagnosed with severe mental illness: Radio Nikosia.
- Author
-
Rojo-Pardo C and Iñiguez-Rueda L
- Subjects
- Humans, Radio, Mental Disorders diagnosis, Self Concept
- Abstract
This article examines the discursive approach adopted by Radio Nikosia, highlighting its crucial role in the recovery of people diagnosed with severe mental illness. It examines how putting social representations aside has enabled Radio Nikosia to render agency to these social actors, acknowledging their capacity to construct, reconstruct and change their own identities. The geographic scope of the study comprises the Autonomous Community of Catalonia while the methodology followed is qualitative in nature, analysing programme audio and transcription, reports, academic articles, theses, and a participant interview. The aim of the analysis is to examine the significance of discursive practices in Radio Nikosia in modifying the permanence of identities anchored in severe mental illness. The results illustrate the practical use of radio as a powerful tool that both promotes social inclusion and impacts mental illness identity.
- Published
- 2023
- Full Text
- View/download PDF
13. Role of Micronutrients and Gut Microbiota-Derived Metabolites in COVID-19 Recovery.
- Author
-
Hernández-Flores TJ, Pedraza-Brindis EJ, Cárdenas-Bedoya J, Ruíz-Carrillo JD, Méndez-Clemente AS, Martínez-Guzmán MA, and Iñiguez-Gutiérrez L
- Subjects
- Humans, Aged, Micronutrients pharmacology, Vitamins pharmacology, Coenzymes, Gastrointestinal Microbiome, COVID-19
- Abstract
A balanced and varied diet provides diverse beneficial effects on health, such as adequate micronutrient availability and a gut microbiome in homeostasis. Besides their participation in biochemical processes as cofactors and coenzymes, vitamins and minerals have an immunoregulatory function; meanwhile, gut microbiota and its metabolites coordinate directly and indirectly the cell response through the interaction with the host receptors. Malnourishment is a crucial risk factor for several pathologies, and its involvement during the Coronavirus Disease 2019 pandemic has been reported. This pandemic has caused a significant decline in the worldwide population, especially those with chronic diseases, reduced physical activity, and elder age. Diet and gut microbiota composition are probable causes for this susceptibility, and its supplementation can play a role in reestablishing microbial homeostasis and improving immunity response against Coronavirus Disease 2019 infection and recovery. This study reviews the role of micronutrients and microbiomes in the risk of infection, the severity of disease, and the Coronavirus Disease 2019 sequelae., Competing Interests: The authors declare no conflict of interest.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.